Kiniksa Pharmaceuticals International (KNSA) Net Income towards Common Stockholders (QoQ) (2017 - 2026)
Kiniksa Pharmaceuticals International (KNSA) Net Income towards Common Stockholders (QoQ) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Kiniksa Pharmaceuticals International | 6.14 Bn | 5.61 Bn | 220.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.57% |
| Mar 31, 2026 | 59.11% |
| Dec 31, 2025 | -22.98% |
| Sep 30, 2025 | 3.38% |
| Jun 30, 2025 | 108.83% |
| Mar 31, 2025 | 196.07% |
| Dec 31, 2024 | 29.98% |
| Sep 30, 2024 | -224.80% |
| Jun 30, 2024 | 77.93% |
| Mar 31, 2024 | 64.05% |
| Dec 31, 2023 | -255.42% |
| Sep 30, 2023 | -192.54% |
| Jun 30, 2023 | 222.02% |
| Mar 31, 2023 | -113.86% |
| Dec 31, 2022 | -60.49% |
| Sep 30, 2022 | 1,221.53% |
| Jun 30, 2022 | 20.74% |
| Mar 31, 2022 | 42.81% |
| Dec 31, 2021 | -44.31% |
| Sep 30, 2021 | 26.51% |